Your Health, We Care
Release date: 2024-08-27 15:07:53 Recommended: 133
Alpelisib was approved by the FDA in 2019 as a PIK3CA kinase inhibitor in combination with fulvestrant, providing a new treatment option for patients with advanced breast cancer with HR/HER2- and PIK3CA mutations.
When using the drug, patients should pay attention to the following precautions to reduce potential side effects.
Fasting blood glucose and HbA1c are checked before treatment, and weekly for the first two weeks after treatment and every four weeks thereafter. High-risk patients require more frequent monitoring and treatment adjustments.
If you experience hypoxia, cough, or difficulty breathing, stop the drug immediately and check for pneumonia. After the diagnosis of non-infectious pneumonia, the drug should be permanently discontinued, and changes in respiratory symptoms should be reported.
It is important for patients to understand the precautions of the drug, and the potential adverse effects of the drug should not be overlooked.
The use of Alpelisib may trigger some potential adverse effects, which are organized below according to the drug leaflet.
The drug can trigger an allergic skin reaction, such as a rash, itching or scaling. In severe cases, medications may need to be adjusted or stopped to relieve these symptoms.
The medication may cause digestive upset, frequent diarrhea. Diarrhea may be accompanied by abdominal pain or stomach upset, and long-term diarrhea can trigger dehydration.
Understanding common adverse reactions can help patients deal with them in a timely manner; Patients should also be aware of the special population use of the drug before using it.
Special attention should be paid to the use of drugs in special populations, and the following is a guide to the use of Alpelisib in these populations.
The results of the trial showed that the incidence of hyperglycemia was higher in older patients over 65 years of age, but the efficacy was comparable to that of patients of other ages. Data are currently limited in patients over 75 years of age, and it is not possible to fully assess the effectiveness of the drug in this age group.
There is no data on whether Alpelisib goes into breast milk. Breastfeeding women are advised to stop breastfeeding while taking the drug and for a week after the last dose.
Understanding medication guidance for these special populations can help patients better manage the treatment process.
[Warm tips] Patients should have a comprehensive understanding of the precautions for the use of drugs, adverse reactions, and medication for special populations, and then use drugs according to the doctor's instructions after a comprehensive understanding, which is conducive to the recovery of patients.
